Blood donor screening for West Nile virus (WNV) revealed acute Usutu virus (USUV) infection, Germany, September 2016

D Cadar1,2, P Maier3, S Müller4, J Kress4, M Chudy4, A Bialonski1, A Schlaphof1, S Jansen4, H Jöst5, E Tannich1, S Runkel4, WE Hitzler5, G Hutschenreuter3, M Wessiepe3,6, J Schmidt-Chanasit1,2

1. Bernhard Nocht Institute for Tropical Medicine, WHO Collaborating Centre for Arbovirus and Hemorrhagic Fever Reference and Research, Hamburg, Germany
2. German Centre for Infection Research (DZIF), partner site Hamburg-Luebeck-Borstel, Hamburg, Germany
3. Institute for Transfusion Medicine, University Hospital, Aachen, Germany
4. Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany
5. Transfusion Center, University Medical Center of the J.G. University, Mainz, Germany
6. These authors contributed equally to this work

Correspondence: Jonas Schmidt-Chanasit (jonassi@gmx.de)

Citation style for this article:

Between 1 June and 31 December 2016, 13,023 blood donations from the University Hospital Aachen in Germany were routinely screened for West Nile virus (WNV) RNA using the cobas TaqScreen WNV Test. On 28 September 2016, one blood donor was tested positive. Subsequent analysis revealed an acute Usutu virus (USUV) infection. During the ongoing USUV epizootics in Germany, blood transfusion services, public health authorities and clinicians should be aware of increased human USUV infections.

Case description
On 26 September 2016, a plasma pool (n=16) had been detected WNV-positive (Ct: 40.5) using cobas TaqScreen WNV Test (Roche Diagnostics GmbH, Mannheim, Germany) with a sensitivity of 206.4 copies/mL per single donation. In order to detect the positive plasma sample, each sample from the pool was tested individually and the positive sample identified (Ct: 37.5). The blood donor was a German woman in her late 20s, without any travel history outside Germany in the previous 7 months. Furthermore, she had not left the Aachen region at all in the 3 months prior to blood donation. The healthy donor had not experienced any symptoms in the 6 weeks before donation. She reported several mosquito bites before the donation. Blood and urine samples of the donor were sent to the WHO CC in Hamburg for further characterisation. Results of IgG and IgM immunofluorescent assays for WNV, USUV, tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JEV) were negative (titres <1:20) for the first sample collected on 26 September 2016. In contrast, IgG and IgM seroconversion was demonstrated with the follow up sample collected on 20 November 2016, 55 days later and the results for WNV-IgG (1:160), WNV-IgM (1:160), TBEV-IgG (1:20), TBEV-IgM (1:20), JEV-IgG (1:640), and JEV-IgM (1:80) and USUV-IgG (1:1280) and USUV-IgM (1:640) suggested a recent USUV infection. The blood donor reported no history of vaccination against YFV and JEV. Extracted RNA of plasma and urine samples were tested for the presence of flavivirus RNA with pan-flavivirus RT-PCR [2]. A positive PCR result was obtained with RNA from the plasma sample and direct Sanger sequencing of the PCR amplicon showed USUV nucleic acid sequence.
Figure 1
Bayesian maximum clade credibility tree representing the phylogenetic placement of the human Usutu virus (USUV) strain Aachen compared with all available USUV based on partial NS5 gene nt sequences.
Attempts to isolate USUV in cell culture using the donor plasma were not successful.

**Deep sequencing and genetic analysis**

The concentrated and purified RNA was further subjected to deep-sequencing using in-house next-generation sequencing pipeline in order to obtain larger fragments of the USUV genome. Thereby, we were able to successfully recover about 60% of the USUV polyprotein gene. USUV from the donor plasma showed 99% homology with those found in the birds during the 2016 epizootics corresponding with the same region from where the donor originated (Figure 1). Phylogenetic analysis demonstrated that USUV ‘Aachen’ strain clustered together with the 2016 outbreaks strains and formed together with some German and Belgian strains a distinct subclade within the previously assigned European lineage 3 (Figure 1).

The analysis of the polyprotein gene revealed several host-specific unique amino acid mutations from which three were located in domain II of the envelope glycoprotein (Figure 2).

**Background**

USUV, an Old World flavivirus included in the JEV antigenic complex is transmitted by mosquitoes to birds that act as the main amplifying hosts, while humans are considered incidental or dead-end hosts [3]. Since the first emergence in the mid-1990s in Europe, USUV has been responsible for smaller periodic epizootics in several European countries, the largest one being
registered in 2016 [1,4-6]. USUV can cause Usutu fever in humans with mild to severe symptoms characterised by fever, rash, jaundice, headache, nuchal rigidity, hand tremor, and hyperreflexia [7-10]. So far, humans were considered incidental hosts with very low prevalence, but recent data from Italy indicated that human USUV infection may not be a sporadic event and is more frequent than WNV infections [11]. In 2012, 1 of 4,200 blood donors from south-west Germany was tested positive for USUV-specific IgG and IgM antibodies demonstrating a recent USUV infection of the donor [12]. However, there is no documented case of Usutu fever caused by transfusion of USUV-contaminated blood products.

Discussion and conclusion

The present report, including serological and molecular findings, suggests an acute and asymptomatic USUV infection of a blood donor in Germany in late summer of 2016. The Bayesian phylogenetic analysis revealed that the USUV sequence of the blood donor had a high sequence homology with recent strains responsible for the 2016 USUV epizootics in the western part of Germany from where the donor lived. Since the blood donor had no history of travelling abroad in the 7 months before the end of September 2016, she must have been infected in Germany, which, together with the genetic data obtained, further strengthens an autochthonous USUV infection in the Aachen region.

USUV is considered an emerging arbovirus due to its rising incidence of human infections that are likely to be frequent as WNV infections and the expansion in new, previously known USUV-free areas [1,11]. It is interesting to note the amino acid mutations detected mostly in the envelope protein and NS5 gene. Although the biological consequences of these mutations are not known, similar changes in the related WNV increased the sensitivity to neutralisation by a monoclonal antibody targeting a cryptic epitope in the fusion loop and altered tropism and neuroinvasive capacity [13,14].

The detection of USUV RNA in the blood donor sample using cobas TaqScreen WNV Test, demonstrates the capability of this test to detect other flaviviruses than WNV due to cross-reactivity of the used primer-probe reagents.

To address the emergence of WNV regarding blood safety, the Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich-Institut) as the responsible authority in Germany, implemented a regulation for non-pathogen inactivated blood components in 2003, last updated in 2014 [15]. Since the update in 2014, alternatively to the deferral period of 28 days, donor eligibility is accepted indicating a non-reactive screening result using a nucleic acid amplification technique (NAT)-based test for WNV RNA with a minimum detection sensitivity of 250 copies/mL for each donor sample [15].

Recent molecular and serologic surveillance studies in Germany and neighbouring countries identified epizootic hotspots for USUV that could help to initiate targeted vector control programs to prevent human exposure to the virus [1,3,16,17]. Moreover, the present report highlights the potential risk of transfusion-associated transmission of USUV. However, until now there is no reported case of transfusion-associated Usutu fever in Europe. The demonstrated case should raise awareness of the risk of USUV infection in humans during epizootics, especially in late summer.

Acknowledgements

This work was financially supported by the German Federal Ministry of Food and Agriculture (BMEL) through the Federal Office for Agriculture and Food (BLE) with the grant number 28-1-91.048-15. We would like to thank Christina Frank and Ruth Offergeld (Robert Koch-Institut) for helpful comments regarding blood safety regulations in Germany.

Conflict of interest

None declared.

Authors’ contributions

Wrote the manuscript: DC, JSC, ET, PM, MW, GH, WEH;
Performed laboratory or epidemiological investigations: DC, JK, JSC, AR, SM, MC, AS, SR, MW, AB, Sl, HI; Performed data analysis: DC, JSC, SR, MW.

References


License and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2017.